Leukocyte adhesion molecule dynamics after Natalizumab withdrawal in Multiple Sclerosis

• Published in: Clinical immunology (Orlando, Fla.) Vol. 171; pp. 18 - 24
• Main Authors: Álvaro, Cobo-Calvo, Agnes, Figueras, Laura, Bau, Elisabet, Matas, Alba, Mañé- Martínez María, Isabel, León, Carles, Majòs, Lucia, Romero-Pinel, Sergio, Martínez-Yélamos
• Format: Journal Article
• Language: English
• Published: United States 01.10.2016
• Subjects: Adult; Allergy and Immunology; Antigens, CD - immunology; CD4-Positive T-Lymphocytes - immunology; CD8-Positive T-Lymphocytes - immunology; Cell Adhesion Molecules - immunology; Female; Humans; Immunologic Factors - pharmacology; Immunologic Factors - therapeutic use; Integrin alpha4beta1 - immunology; Male; Middle Aged; Multiple Sclerosis - drug therapy; Multiple Sclerosis - immunology; Natalizumab - pharmacology; Natalizumab - therapeutic use; Young Adult; Multiple Sclerosis; Adhesion molecules; Natalizumab withdrawal; Dynamics; VLA-4
• ISSN: 1521-6616; 1521-7035
• DOI: 10.1016/j.clim.2016.08.003

Abstract Cell- adhesion molecules (CAMs) dynamics in Multiple Sclerosis (MS) patients have been widely studied after Natalizumab (NTZ) introduction. However, their temporal dynamics after NTZ withdrawal (NTZ-W) has not been described. We prospectively evaluate changes in the expression levels of CAMs (CD49d, CD29, L-Selectin and CD11a) involved in T cell migration of 22 MS patients after NTZ-W. CD49d, CD29 and CD11a expression experienced a continuous increase expression two months after NTZ-W and Cd49d expression at month six after NTZ-W correlated to NTZ treatment duration, both in CD45+ CD4+ and CD45+ CD8+ . CD49d expression up to month three after NTZ-W was related to MS activity in CD45+ CD8+ at the end of the study. Results from this study suggest that patients with a longer NTZ treatment are more susceptible to present a “molecular rebound” after NTZ-W. CD49d determination may be a useful tool to closely monitor MS activity in patients who interrupt NTZ.